BioSpace News Archive

Enteris BioPharma, Inc. and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today the publication of a new white paper entitled, “HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Power, Precision and Productivity.”

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), is pleased to announce that the U.S. FDA has approved the Company’s proprietary psilocybin drug Orphan Drug Application to treat patients with fragile X syndrome (FXS),

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2021 and provided an update on recent business performance and strategic transformation plans.

Viveve Medical, Inc. today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 11, 2021.

Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced that it will release its financial results for the second quarter ended September 30, 2021, on Thursday, November 4, 2021, after the close of the market.

Aggarwal and Associates Limited announced plans to operate as a study site for, and begin enrolling participants into, the global Phase 3 RENOIR.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today announced it has appointed Michael E. Stern, MS, Ph.D., to its Medical Advisory Board.

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, announced the appointment of Jennifer Reyntjes as Chief People Officer.

EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, has signed a lease for 14,000 square feet of lab and office space in the Greater Boston area to house the company’s growing U.S. R&D Center.

The trial is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate the Company’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy.